Mark A. Varney

TL;DR: Targeting 5-HT1A receptors with selective biased agonists exerts distinct effects in the rat model of PD and LID and could potentially translate to superior antidyskinetic and L-DOPA dose-sparing effects in PD patients.

TL;DR: NLX-112 could exhibit a novel therapeutic profile, combining robust anti-dyskinetic properties without impairing the therapeutic properties of L-DOPA, and with additional beneficial effects on non-motor (affective) symptoms.

TL;DR: It is suggested that the novel biased agonist F15599 combines pronounced activity in a test of anxiety with potent antidepressant-like effects and low propensity to induce serotonergic behaviors and that selective biased agonists could constitute promising pharmacotherapeutics for mood disorders.

TL;DR: These data suggest that the F‐series compounds articulate their anti‐LID effects through activation of a diverse set of striatal 5‐HT1A hetero‐receptor populations, and play an important role in the anti-LID and pro‐5‐HT syndrome profiles of F13714 and F15599.

TL;DR: Mechanisms by which pattern separation can be increased are of potential therapeutic interest because it is an important hippocampal process implicated in cognitive domains like episodic memory.